每經訊(xun)，托(tuo)(tuo)球股(gu)(gu)份5月20日發布公(gong)(gong)(gong)告(gao)稱，根據公(gong)(gong)(gong)司(si)(si)(si)(si)發展戰略，公(gong)(gong)(gong)司(si)(si)(si)(si)擬對控(kong)股(gu)(gu)子(zi)公(gong)(gong)(gong)司(si)(si)(si)(si)托(tuo)(tuo)球生物科技有(you)限(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)增加(jia)注(zhu)冊資(zi)(zi)本(ben)人民(min)幣2.2億元，增資(zi)(zi)后托(tuo)(tuo)球生物科技有(you)限(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)注(zhu)冊資(zi)(zi)本(ben)為人民(min)幣5.2億元。增資(zi)(zi)后公(gong)(gong)(gong)司(si)(si)(si)(si)持(chi)有(you)托(tuo)(tuo)球生物科技有(you)限(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)96.54%的股(gu)(gu)權。2025年05月20日，公(gong)(gong)(gong)司(si)(si)(si)(si)召開了第四(si)屆(jie)董(dong)事會(hui)第五次會(hui)議(yi)，審議(yi)通過(guo)《關(guan)于向控(kong)股(gu)(gu)子(zi)公(gong)(gong)(gong)司(si)(si)(si)(si)增資(zi)(zi)的議(yi)案》，根據《公(gong)(gong)(gong)司(si)(si)(si)(si)章(zhang)程》等相(xiang)關(guan)規定，本(ben)議(yi)案尚需提交公(gong)(gong)(gong)司(si)(si)(si)(si)股(gu)(gu)東大會(hui)審議(yi)。

（記者 曾健輝）

免責聲明：本文內容與(yu)數據僅供(gong)參考(kao)，不構成投資(zi)建議，使(shi)用前請核實。據此(ci)操作，風(feng)險自擔(dan)。